DiabetesNCT04790760
Glucose Differences Between the Left Arm and Right Arm in Diabetic Patients Using a Continuous Glucose Monitor
A study testing Supplement Consumption and Continuous Glucose Monitors in people with Diabetes, run by University of the Pacific at 1 site in United States.
Trial summary
Continuous glucose monitoring (CGM) is an emerging field for diabetes management. CGMs are small devices primarily placed on a patient's upper arm that allow providers and patients to individualize therapy by looking at real time glucose levels. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Diabetes
- What is being tested?
- Supplement Consumption and Continuous Glucose Monitors
- Type of treatment
- Pill or oral medicine, Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 10 participants
- Where
- 1 siteUnited States
- Study dates
- Mar 2021to Feb 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adult 18-65 years of age
- Diagnosed with type 2 diabetes
- Willing to wear CGM for 6 weeks on both arms
- Willing to come in for 4 office visits over 6 weeks
- Willing to consume assigned supplement twice a day for 4 weeks
- Willing to receive and respond to daily text messages or maintain a daily study log of supplement consumption
Show all 12Show fewer
- Have active health insurance
- Willing to refrain from any heat therapy for the duration of the study
- Willing to refrain from taking any other supplements that are deemed by the investigator to alter glucose for the duration of the study
- Willing to refrain from consuming ascorbic acid and salicylic acid for the duration of the study due to a known interaction with CGMs
- Be able to self-monitor blood glucose with finger-stick method
- Have a baseline HbA1c > 6.5%
Who cannot join
- Any active dermatologic condition on the upper arms
- Implanted medical devices (i.e. pacemaker)
- Critically ill or dialysis patients
- Planned magnetic resonance imaging screening, computed tomography scan, x-ray imaging or high-frequency electrical heat treatment during study period
- Current systemic infections
- Participants who are unable to fully understand the study or consent process will not be included in the study due to the lack of a qualified medical translator
Show all 11Show fewer
- Change in diabetic medication regimen within the previous 30 days (except insulin)
- Self-identified allergy to cinnamon or aloe vera
- Refusal to sign the informed consent document
- Pregnant, planned-pregnancy during study period or currently breast-feeding
- History of hypoglycemic episodes warranting medical attention experienced in the last 30 days
Trial locations and contacts
1 site in 1 country.
United States1 site, 1 recruiting
- Recruiting
Manshadi Heart Institute, Inc.
Stockton, California, 95204
Sachin Shah
About this study
Continuous glucose monitoring (CGM) is an emerging field for diabetes management. CGMs are small devices primarily placed on a patient's upper arm that allow providers and patients to individualize therapy by looking at real time glucose levels. While the accuracy of these devices is extensively researched, there are no large-scale studies evaluating the differences between left and right arm glucose readings in the diabetic population. Additionally cinnamon and aloe vera are supplements commonly used by diabetic patients to help improve glycemic control. However, there remains a shortage of studies researching the effects of cinnamon and aloe vera on diabetic patients' glycemic control.
The purpose of this study is to determine if there is a difference between glucose levels in the right arm and left arm in diabetic patients and to evaluate if cinnamon and aloe vera supplements impact glycemic control in diabetic patients.
Read the detailed description
Continuous glucose monitoring (CGM) is an emerging field for diabetes management. CGMs allow providers to individualize therapy by looking at real time glucose levels, detect changes in glucose and raise awareness for hypo- and hyperglycemic events.[1] Some CGMs can be placed on the patient's arm to monitor glucose at regular intervals. The data is downloaded onto a reader where it can be viewed or sent to a computer for more in depth analysis. There are multiple Food and Drug Administration (FDA) approved CGM devices. The FDA considers a device to be accurate if 99% of glucose measurements are within 20% of lab results and if 95% of glucose measurements are within 15% of lab results.[2]
The accuracy and precision of CGMs is improving with increased use and advancement of the systems in use. CGM data has been deemed accurate for self use to adjust insulin dosage, detection of hypoglycemia and determining the clinical response to therapy.[3] However, CGMs are a new technology and while they have vastly improved since they originally came to market, there are still many concerns over their accuracy and ability to inform clinical treatment decisions.[3] An analysis conducted on the reports to the FDA Manufacturer and User Facility Device Experience (MAUDE) database since 2015 revealed over 25,000 complaints of CGM inaccuracy.[4]
In the American Diabetes Association (ADA) 2020 Guidelines on the Standards of Medical Care in Diabetes, it is stated that glycemic goals are achieved through glucose monitoring and, as such, self monitoring blood glucose is essential for reaching these goals.[5] CGMs are used to guide the treatment of diabetes including pharmacologic intervention, recommendations for hypoglycemia prevention and nutrition goals. The recommended time spent in range, time above range and time below range are also outlined in these guidelines.[5] The significance of time below range is associated with the risk of hypoglycemia. The more time spent below range is going to increase the chance of experiencing a hypoglycemic event which, if experienced, will have both negative physical and psychological effects on the person. In the most severe cases it can also lead to seizures, coma and death.[5] Increased time spent above range has been directly correlated with incidence and progression of microvascular complications associated with diabetes like retinopathy, neuropathy and kidney disease.[5] Time spent in range is also significant because in addition to informing treatment decisions, it has also been correlated to improvements in hemoglobin A1c (HbA1c). In a recent analysis of 18 studies reporting paired HbA1c and time in range (%), it was found that for every 10% change in time in range, there was a corresponding 0.8% change in HbA1c.[6] This could mean that if a person spends 10% more time in range, their HbA1c may reduce up to 0.8%. This is significant since HbA1c is a gold standard marker of glycemic control in the diabetic population.[5]
Based on previous studies, the evaluation of CGM readings in the left and right arms of diabetic patients is needed. The information provided by CGMs outside of glucose levels such as time range information, hyper- or hypoglycemic glucose levels, and even immediate phone alerts for very low or very high readings in newer devices highlights the ever growing and critical role these devices play in the care of diabetic patients, and as such their accuracy and proper use is of the utmost importance.[7]
Cinnamon and aloe vera supplements are available over the counter and are used by consumers for many different ailments. Both cinnamon and aloe vera have been used for several centuries across many different cultures for a wide range of medicinal purposes. Diabetes is an example of one of the disease states commonly targeted by these two supplements. Patients with diabetes frequently consume cinnamon and aloe vera dietary supplements in an effort to improve their glycemic control. As research into the effects of these supplements has expanded, the understanding of their safety and practical uses has become better understood and is generally accepted.[8,9] There are many dietary supplements or food classified cinnamon and aloe vera based products on the market. Both cinnamon and aloe vera are Generally Recognized As Safe (GRAS status). However there is a lack of long term evaluation of the effects of these supplements in the diabetic patient population.
This study is a controlled, prospective trial that aims to evaluate the difference in glucose readings between the right arm and left arm using continuous glucose monitors in diabetic patients. In addition this study aims to evaluate the effect of cinnamon and aloe vera supplementation on glycemic control in diabetic patients.
- Conditions
- Diabetes
- Being tested
- Supplement Consumption, Continuous Glucose Monitors
- Medical subject headings
- Diabetes Mellitus
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Supplement ConsumptionDietary supplement
Participants will consume one 500 mg cinnamon capsule and one 300 mg aloe vera capsule twice per day for weeks 3-6.
Continuous Glucose MonitorsDevice
Participants will wear a CGM on the back of their left and right arm for weeks 1-6.
| Study group | Role | What they receive |
|---|---|---|
| Continuous Glucose Monitoring | Experimental | Participants will wear a CGM device on the back of both their left and right arm for 6 weeks. Receives: Dietary Supplement: Supplement Consumption; Device: Continuous Glucose Monitors |
What is being measured
The primary outcome is the main question the study is designed to answer.
Difference in time-matched glucose levels between the right arm and the left arm
Measured: 6 weeks
Secondary outcomes (3)
Difference in time in range between the right arm and the left arm
Measured: 6 weeks
Difference in time above range between the right arm and the left arm
Measured: 6 weeks
Difference in time below range between the right arm and the left arm
Measured: 6 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Mar 2021
- Study startMar 2021 (estimated)
- Primary completionFeb 2022 (estimated)
- Study completionFeb 2022 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (9)Papers the sponsor has linked to this study.
- Other trials for DiabetesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 10 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of the Pacific
- Sponsor type
- University, hospital or other
- Collaborators
- Manshadi Heart Institute, Inc.
- Responsible party
- Sponsor
- Investigators
- Sachin Shah, PharmD, Principal investigator, University of the Pacific
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04790760
- Sponsor's protocol ID
- 20-29
- Status last verified
- Feb 2021
- First submitted
- 19 Feb 2021
- Last updated
- 10 Mar 2021
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Publications
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group; Beck RW, Hirsch IB, Laffel L, Tamborlane WV, Bode BW, Buckingham B, Chase P, Clemons R, Fiallo-Scharer R, Fox LA, Gilliam LK, Huang ES, Kollman C, Kowalski AJ, Lawrence JM, Lee J, Mauras N, O'Grady M, Ruedy KJ, Tansey M, Tsalikian E, Weinzimer SA, Wilson DM, Wolpert H, Wysocki T, Xing D. The effect of continuous glucose monitoring in well-controlled type 1 diabetes. Diabetes Care. 2009 Aug;32(8):1378-83. doi: 10.2337/dc09-0108. Epub 2009 May 8.
PubMed 19429875Food and Drug Administration. Self-monitoring blood glucose test systems for over-the-counter use-guidance for industry and food and drug administration staff. Available at: http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM380327.pdf. Accessed October 10, 2016.
Siegmund T, Heinemann L, Kolassa R, Thomas A. Discrepancies Between Blood Glucose and Interstitial Glucose-Technological Artifacts or Physiology: Implications for Selection of the Appropriate Therapeutic Target. J Diabetes Sci Technol. 2017 Jul;11(4):766-772. doi: 10.1177/1932296817699637. Epub 2017 Mar 21.
PubMed 28322063Shapiro AR. Nonadjunctive Use of Continuous Glucose Monitors for Insulin Dosing: Is It Safe? J Diabetes Sci Technol. 2017 Jul;11(4):833-838. doi: 10.1177/1932296816688303. Epub 2017 Mar 1.
PubMed 28540756American Diabetes Association. 6. Glycemic Targets: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020 Jan;43(Suppl 1):S66-S76. doi: 10.2337/dc20-S006.
PubMed 31862749Vigersky RA, McMahon C. The Relationship of Hemoglobin A1C to Time-in-Range in Patients with Diabetes. Diabetes Technol Ther. 2019 Feb;21(2):81-85. doi: 10.1089/dia.2018.0310. Epub 2018 Dec 21.
PubMed 30575414FreeStyle Libre 2-Best Glucose Monitor For Kids - Coming Soon for Patients 4+. Continuous Glucose Monitoring System. https://www.freestylelibre.us/system-overview/freestyle-libre-2.html. Accessed June 21, 2020.
Kawatra P, Rajagopalan R. Cinnamon: Mystic powers of a minute ingredient. Pharmacognosy Res. 2015 Jun;7(Suppl 1):S1-6. doi: 10.4103/0974-8490.157990.
PubMed 26109781Foster M, Hunter D, Samman S. Evaluation of the Nutritional and Metabolic Effects of Aloe vera. In: Benzie IFF, Wachtel-Galor S, editors. Herbal Medicine: Biomolecular and Clinical Aspects. 2nd edition. Boca Raton (FL): CRC Press/Taylor & Francis; 2011. Chapter 3. Available from: https://www.ncbi.nlm.nih.gov/books/NBK92765/
Study at a glance
From the registry record, last updated by the sponsor on 10 Mar 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Glucose Differences Between the Left Arm and Right Arm in Diabetic Patients Using a Continuous Glucose Monitor
- ClinicalTrials.gov ID
- NCT04790760
- Acronym / sponsor ID
- 20-29
- Conditions
- Diabetes
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 10 participants (estimated)
- Lead sponsor
- University of the PacificUniversity, hospital or other
- Collaborators
- Manshadi Heart Institute, Inc.
- Study start
- Mar 2021 (estimated)
- Primary completion
- Feb 2022 (estimated)
- Study completion
- Feb 2022 (estimated)
- First posted
- 10 Mar 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Continuous glucose monitoring (CGM) is an emerging field for diabetes management. CGMs are small devices primarily placed on a patient's upper arm that allow providers and patients to individualize therapy by looking at real time glucose levels. While the accuracy of these devices is extensively researched, there are no large-scale studies evaluating the differences between left and right arm glucose readings in the diabetic population. Additionally cinnamon and aloe vera are supplements commonly used by diabetic patients to help improve glycemic control. However, there remains a shortage of studies researching the effects of cinnamon and aloe vera on diabetic patients' glycemic control.
The purpose of this study is to determine if there is a difference between glucose levels in the right arm and left arm in diabetic patients and to evaluate if cinnamon and aloe vera supplements impact glycemic control in diabetic patients.
Detailed description
Continuous glucose monitoring (CGM) is an emerging field for diabetes management. CGMs allow providers to individualize therapy by looking at real time glucose levels, detect changes in glucose and raise awareness for hypo- and hyperglycemic events.[1] Some CGMs can be placed on the patient's arm to monitor glucose at regular intervals. The data is downloaded onto a reader where it can be viewed or sent to a computer for more in depth analysis. There are multiple Food and Drug Administration (FDA) approved CGM devices. The FDA considers a device to be accurate if 99% of glucose measurements are within 20% of lab results and if 95% of glucose measurements are within 15% of lab results.[2]
The accuracy and precision of CGMs is improving with increased use and advancement of the systems in use. CGM data has been deemed accurate for self use to adjust insulin dosage, detection of hypoglycemia and determining the clinical response to therapy.[3] However, CGMs are a new technology and while they have vastly improved since they originally came to market, there are still many concerns over their accuracy and ability to inform clinical treatment decisions.[3] An analysis conducted on the reports to the FDA Manufacturer and User Facility Device Experience (MAUDE) database since 2015 revealed over 25,000 complaints of CGM inaccuracy.[4]
In the American Diabetes Association (ADA) 2020 Guidelines on the Standards of Medical Care in Diabetes, it is stated that glycemic goals are achieved through glucose monitoring and, as such, self monitoring blood glucose is essential for reaching these goals.[5] CGMs are used to guide the treatment of diabetes including pharmacologic intervention, recommendations for hypoglycemia prevention and nutrition goals. The recommended time spent in range, time above range and time below range are also outlined in these guidelines.[5] The significance of time below range is associated with the risk of hypoglycemia. The more time spent below range is going to increase the chance of experiencing a hypoglycemic event which, if experienced, will have both negative physical and psychological effects on the person. In the most severe cases it can also lead to seizures, coma and death.[5] Increased time spent above range has been directly correlated with incidence and progression of microvascular complications associated with diabetes like retinopathy, neuropathy and kidney disease.[5] Time spent in range is also significant because in addition to informing treatment decisions, it has also been correlated to improvements in hemoglobin A1c (HbA1c). In a recent analysis of 18 studies reporting paired HbA1c and time in range (%), it was found that for every 10% change in time in range, there was a corresponding 0.8% change in HbA1c.[6] This could mean that if a person spends 10% more time in range, their HbA1c may reduce up to 0.8%. This is significant since HbA1c is a gold standard marker of glycemic control in the diabetic population.[5]
Based on previous studies, the evaluation of CGM readings in the left and right arms of diabetic patients is needed. The information provided by CGMs outside of glucose levels such as time range information, hyper- or hypoglycemic glucose levels, and even immediate phone alerts for very low or very high readings in newer devices highlights the ever growing and critical role these devices play in the care of diabetic patients, and as such their accuracy and proper use is of the utmost importance.[7]
Cinnamon and aloe vera supplements are available over the counter and are used by consumers for many different ailments. Both cinnamon and aloe vera have been used for several centuries across many different cultures for a wide range of medicinal purposes. Diabetes is an example of one of the disease states commonly targeted by these two supplements. Patients with diabetes frequently consume cinnamon and aloe vera dietary supplements in an effort to improve their glycemic control. As research into the effects of these supplements has expanded, the understanding of their safety and practical uses has become better understood and is generally accepted.[8,9] There are many dietary supplements or food classified cinnamon and aloe vera based products on the market. Both cinnamon and aloe vera are Generally Recognized As Safe (GRAS status). However there is a lack of long term evaluation of the effects of these supplements in the diabetic patient population.
This study is a controlled, prospective trial that aims to evaluate the difference in glucose readings between the right arm and left arm using continuous glucose monitors in diabetic patients. In addition this study aims to evaluate the effect of cinnamon and aloe vera supplementation on glycemic control in diabetic patients.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Continuous Glucose Monitoring | Experimental | Dietary Supplement: Supplement Consumption, Device: Continuous Glucose MonitorsParticipants will wear a CGM device on the back of both their left and right arm for 6 weeks. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (12 listed)
- Adult 18-65 years of age
- Diagnosed with type 2 diabetes
- Willing to wear CGM for 6 weeks on both arms
- Willing to come in for 4 office visits over 6 weeks
- Willing to consume assigned supplement twice a day for 4 weeks
Key exclusion criteria (11 listed)
- Any active dermatologic condition on the upper arms
- Implanted medical devices (i.e. pacemaker)
- Critically ill or dialysis patients
- Planned magnetic resonance imaging screening, computed tomography scan, x-ray imaging or high-frequency electrical heat treatment during study period
- Current systemic infections
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Supplement ConsumptionParticipants will consume one 500 mg cinnamon capsule and one 300 mg aloe vera capsule twice per day for weeks 3-6. | Dietary supplement | Continuous Glucose Monitoring |
| Continuous Glucose MonitorsParticipants will wear a CGM on the back of their left and right arm for weeks 1-6. | Device | Continuous Glucose Monitoring |
Primary outcome
Difference in time-matched glucose levels between the right arm and the left arm
Time frame: 6 weeks
3 secondary outcomes
Difference in time in range between the right arm and the left arm
Time frame: 6 weeks
Difference in time above range between the right arm and the left arm
Time frame: 6 weeks
Difference in time below range between the right arm and the left arm
Time frame: 6 weeks
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Mar 2021.
- Background: PubMed 19429875Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group; Beck RW, Hirsch IB, Laffel L, Tamborlane WV, Bode BW, Buckingham B, Chase P, Clemons R, Fiallo-Scharer R, Fox LA, Gilliam LK, Huang ES, Kollman C, Kowalski AJ, Lawrence JM, Lee J, Mauras N, O'Grady M, Ruedy KJ, Tansey M, Tsalikian E, Weinzimer SA, Wilson DM, Wolpert H, Wysocki T, Xing D. The effect of continuous glucose monitoring in well-controlled type 1 diabetes. Diabetes Care. 2009 Aug;32(8):1378-83. doi: 10.2337/dc09-0108. Epub 2009 May 8.
- BackgroundFood and Drug Administration. Self-monitoring blood glucose test systems for over-the-counter use-guidance for industry and food and drug administration staff. Available at: http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM380327.pdf. Accessed October 10, 2016.
- Background: PubMed 28322063Siegmund T, Heinemann L, Kolassa R, Thomas A. Discrepancies Between Blood Glucose and Interstitial Glucose-Technological Artifacts or Physiology: Implications for Selection of the Appropriate Therapeutic Target. J Diabetes Sci Technol. 2017 Jul;11(4):766-772. doi: 10.1177/1932296817699637. Epub 2017 Mar 21.
- Background: PubMed 28540756Shapiro AR. Nonadjunctive Use of Continuous Glucose Monitors for Insulin Dosing: Is It Safe? J Diabetes Sci Technol. 2017 Jul;11(4):833-838. doi: 10.1177/1932296816688303. Epub 2017 Mar 1.
- Background: PubMed 31862749American Diabetes Association. 6. Glycemic Targets: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020 Jan;43(Suppl 1):S66-S76. doi: 10.2337/dc20-S006.
- Background: PubMed 30575414Vigersky RA, McMahon C. The Relationship of Hemoglobin A1C to Time-in-Range in Patients with Diabetes. Diabetes Technol Ther. 2019 Feb;21(2):81-85. doi: 10.1089/dia.2018.0310. Epub 2018 Dec 21.
- BackgroundFreeStyle Libre 2-Best Glucose Monitor For Kids - Coming Soon for Patients 4+. Continuous Glucose Monitoring System. https://www.freestylelibre.us/system-overview/freestyle-libre-2.html. Accessed June 21, 2020.
- Background: PubMed 26109781Kawatra P, Rajagopalan R. Cinnamon: Mystic powers of a minute ingredient. Pharmacognosy Res. 2015 Jun;7(Suppl 1):S1-6. doi: 10.4103/0974-8490.157990.
- BackgroundFoster M, Hunter D, Samman S. Evaluation of the Nutritional and Metabolic Effects of Aloe vera. In: Benzie IFF, Wachtel-Galor S, editors. Herbal Medicine: Biomolecular and Clinical Aspects. 2nd edition. Boca Raton (FL): CRC Press/Taylor & Francis; 2011. Chapter 3. Available from: https://www.ncbi.nlm.nih.gov/books/NBK92765/
- Individual participant dataSharing planned: No
Related trials for Diabetes
RecruitingObservational study
Genetics of Type 2 Diabetes in West Africans
Hypertension, Diabetes
Not yet recruiting
A Study to Lower Blood Pressure One Year After Childbirth in Women Who Had Preeclampsia
Adverse Pregnancy Outcomes, Cardiovascular Diseases
Not yet recruitingPhase 3
A Study Comparing SHR-3167 With Insulin Degludec in Adults With Type 2 Diabetes Currently Treated With Basal Insulin
Diabetes Mellitus, Type 2
Not yet recruiting
Different Aerobic-to-Resistance Training Ratios in Adults Aged 50 Years and Older With Prediabetes
Prediabetes
Active, not recruiting
Adapting FAMS to Optimize CGM Use Among Emerging Adults With Type 1 Diabetes
Type 1 Diabetes
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sachin Shah, PharmD principal investigator
University of the Pacific
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Supplement Consumption and Continuous Glucose Monitors in people with Diabetes, run by University of the Pacific at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 12 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 10 Mar 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Sachin Shah, PharmD (7074233277, sshah@pacific.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Difference in time-matched glucose levels between the right arm and the left arm (time frame: 6 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04790760, which also lists 9 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Mar 2021.